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Heat shock protein 90 (Hsp90) has been historically
known as an abundant and intracellular ATP-driven
chaperone with more than 100 target proteins that often
play critical roles in various branches of the signaling
networks for control of cell metabolism, survival, growth
and differentiation. In many cancers, Hsp90 is either
over-expressed or over-activated and it, therefore,
becomes a target for anti-cancer drugs with a hope to
simultaneously shut down multiple constitutively acti-
vated oncogene products in cancer cells. Despite of the
high expectations, the toxicity of geldanamycin (GM)-
derived inhibitors in humans has been a long-standing
hurdle. However, studies of past few years have demon-
strated a surprising need for cancer cells to secrete
Hsp90a for tissue invasion and metastasis. I will present
here new evidence that the metastatic breast cancer
cells, MDA-MB-231, constitutively secrete Hsp90a due
to their constitutive expression of the hypoxia-inducible
factor-1alpha (HIF1a). Down-regulation of either HIF1a
or HIF1b completely blocked Hsp90a secretion. The
main function of the secreted Hsp90a is to promote
breast cancer cell motility via binding to the cell surface
lipoprotein receptor LRP1 (LDL Receptor-Related Pro-
tein-1). We have mapped this important extracellular
Hsp90a function to a 27-amino acid peptide located at
the boundary between the linker region (LR) and the
middle domain (M) of Hsp90a. Selective inhibition of
the extracellular action of Hsp90 or down-regulation of
LRP-1 receptor blocked breast cancer invasion in an
in vitro matrigel assay and tumor formation in nude
mice. Most intriguingly, since secretion of Hsp90a was
only found to occur under pathological conditions such
as cancer and is not part of normal cells’ life, anti-
cancer drugs targeting the 27-amino acid peptide of the
extracellular Hsp90a should be more effective and less
toxic in humans. We propose that the novel “secreted
Hsp90-LRP1 Receptor” autocrine signaling plays a role
in breast cancer progression and the extracellular, not
intracellular, Hsp90a is an effective and safer target for
anti-cancer therapies.
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